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We have summarized recently published glomerular parietal epithelial cell (PEC) research, focusing on
their roles in glomerular development and physiology, and in certain glomerular diseases. The rationale is
that PECs have been largely ignored until the recent availability of cell lineage tracing studies, human and
murine PEC culture systems, and potential therapeutic interventions of PECs.
Recent findings
Several new paradigms involving PECs have emerged demonstrating their significant contribution to
glomerular physiology and numerous glomerular diseases. A subset of PECs serving as podocyte
progenitors have been identified in normal human glomeruli. They provide a source for podocytes in
adolescent mice, and their numbers increase in states of podocyte depletion. PEC progenitor number is
increased by retinoids and angiotensin-converting enzyme inhibition. However, dysregulated growth of
PEC progenitors leads to pseudo-crescent and crescent formation. In focal segmental glomerulosclerosis,
considered a podocyte disease, activated PECs increase extracellular matrix production, which leads to
synechial attachment and, when they move to the glomerular tuft, to segmental glomerulosclerosis. Finally,
PECs might be adversely affected in proteinuric states by undergoing apoptosis.
Summary
PECs play a critical role in glomerular repair through their progenitor function, but under certain
circumstances paradoxically contribute to deterioration by augmenting scarring and crescent formation.
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The urinary space of the glomerulus is lined by
Bowman’s basement membrane (commonly called
Bowman’s capsule), upon which attaches a mono-
layer of glomerular parietal epithelial cells (abbre-
viated herein as PECs). In this regard, PECs are
similar to the kidney’s other epithelial cell mono-
layer, namely, podocytes and tubular epithelial
cells. Morphologically, PECs resemble squamous
epithelial cells, with a small cell body size ranging
in thickness from 0.1 to 0.3 mm, increasing to
2.0–3.5 mm at the nucleus. Scanning electron micro-
scopic studies show that PEC surfaces are lined by
microvilli and cilia (0–2 cilia per cell). The functions
of these are not known in this cell type. The number
of PECs in a normal rat glomerulus is estimated to
comprise 14.8% of all glomerular cells. Despite
their thin cell bodies, PECs form junctions between
adjacent cells, comprising a very complicated and
delicate structure, described as ‘labyrinth-like.’iams & Wilkins. UnauthoTransmission electron microscopic studies show
tight junctions near the apical surface of PECs [1].
The study of PECs in health and disease is
increasingly being recognized through vigorous
studies by several investigators globally. This has
been enabled by the generation of primary and
immortalized PECs in culture [2,3], the establish-
ment of reporter mice to cell fate map PECs [4], therized reproduction of this article is prohibited.
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KEY POINTS
 Glomerular PECs serve as progenitors for terminally
differentiated podocytes in healthy glomeruli, and
following a decrease in podocyte number in disease.
 Dysregulated PECs lead to crescent and pseudo-
crescent formation in crescentic and collapsing
glomerulopathies, respectively.
 Several interventions have been shown to regulate
PECs’ progenitor function.
 In FSGS, activated PECs produce extracellular matrix
proteins that form the basis for the synechial
attachments and segmental glomerulosclerosis.
 Tight junction proteins between adjacent PECs likely
serve to limit filtered protein to the urinary space.
Glomerular parietal epithelial cells Shankland et al.identification of proteins and genes expressed by
these cells in normal and diseased experimental
and human conditions, and the application of
molecular and cellular approaches that allow
researchers to begin to probe how these cells may
respond to certain interventions. The purpose of
this review is to provide a recent literature update of
our current understanding of how PEC biology
underlies normal function in health (Table 1),
and how in glomerular diseases PECs may serve a
critical reparative role, or under different circum-
stances the response by PECs may lead to further
glomerular damage.Copyright © Lippincott Williams & Wilkins. Unau
Table 1. Role of parietal epithelial cells in health and dise
Functional role in healthy glomerulus Reparative role of PECs in d
Progenitor function for podocytes PEC progenitors differentiat
podocytes, possibly repla
decreased in disease
Intracellular tight junctions restrict
glomerular filtrate to urinary space
Possible synthesis and repair of
Bowman’s basement membrane
PEC, parietal epithelial cell.
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GOOD GUYS IN DEVELOPMENT, HEALTH,
AND DISEASE
Studies show that PECs are regarded as ‘good guys’ as
they play vital roles during normal glomerular
development, and have critical biological functions
required for normal function in states of health
and disease.Role in normal glomerular development
During nephrogenesis, PECs develop from the meta-
nephric mesenchyme that is induced by the ureteric
bud to gradually acquire an epithelial phenotype
and form the first stage of nephron development,
the renal vesicle, which undergoes a series of inva-
ginations and elongations to generate the S-shaped
bodies [5]. At this stage, the middle and distal
segments of the S-shaped body that remained in
contact with the ureteric bud epithelium fuse to
form a single, continuous epithelial tube. The prox-
imal end is invaded by blood vessels, and Bowman’s
space begins to form [5]. During development from
the S-shaped body to the capillary loop stage, some
PECs constitute Bowman’s capsule, whereas others
upregulate podocyte-specific genes and begin the
de-novo expression of the cyclin-dependent kinase
inhibitor p27, and downregulation of PAX2, to
differentiate into podocytes [5]. The downregula-
tion of PAX2 by WT1 seems to be a prerequisite
that permits this WT1-controlled differentiative




to damage in disease
e into
cing podocytes
Fibrotic attachment and segmental
sclerosis
An uncontrolled/dysregulated proliferation
of PECs and the PEC progenitor
subpopulation leads to excess PEC
number, forming crescents and
pseudo-crescents
Decrease in tight junction protein expression
accompanied by leakage of glomerular
filtrate into periglomerular space
Excess albumin uptake leads to apoptosis,
leading to reduced progenitor pool
Expression pattern consistent with
epithelial-to-mesenchymal transition
Growth factor production and changes in



























FIGURE 1. Signaling pathways regulating parietal epithelial
cell proliferation and their differentiation toward podocytes.
Schematic representation showing the signaling pathways
involved in parietal epithelial cell (PEC) proliferation and
how they are regulated when PECs are pushed to
differentiate toward the podocyte phenotype. In particular,
PECs are pushed to proliferate by high levels of Pax-2,
Notch-2, and cyclin D1 and by the absence of the cell-cycle
inhibitors p21, p27, and p57. High levels of Pax-2 also
suppress WT1 expression, which in turn allows activation of
the b-catenin/Wnt pathway, keeping PECs in an
undifferentiated state. When PECs downregulate Pax-2, this
allows WT1 upregulation, which suppresses the b-catenin/
Wnt pathway that in turn induces PEC differentiation into
podocytes. Differentiation of PECs into podocytes also
associates with upregulation of the cell-cycle inhibitors p21,
p27, p57 and suppression of cyclin D1 and of the Notch
pathway, which makes the podocyte unable to proliferate.
Renal immunology and pathologyb-catenin/Wnt signaling, which represents a pivotal
step driving PEC differentiation into podocytes
during kidney development [7]. Indeed, conditional
b-catenin-knockout mice in which Ctnnb1 (mouse
b-catenin gene) was removed during later stages
of nephrogenesis in PECs show underdeveloped
glomerular capillary tufts, with podocytes replacing
normal flat PECs. These events demonstrate that
b-catenin/Wnt signaling is required for proper
differentiation and maturation of PECs into podo-
cytes [8] (Fig. 1).
Interestingly, the b-catenin/Wnt signaling is also
a direct activator of cyclin D1, a critical initiator of
cell division, which controls PEC proliferation during
development as well as postnatally. Starting at the
S phase of glomerulogenesis, the Src-suppressed
protein kinase C substrate (SSeCKS), a multivalent
scaffolding A kinase anchoring protein which seques-
ters cyclin D1 in the cytoplasm, is induced in embry-
onic PECs, but not in embryonic podocytes, and isopyright © Lippincott Williams & Wilkins. Unautho
304 www.co-nephrolhypertens.comconstitutively expressed postnatally by PECs, but
not podocytes, in normal glomeruli [9
&
] (Fig. 1).
Phosphorylation of SSeCKS by activated protein
kinase C disrupts binding, resulting in nuclear trans-
location of cyclin D1 [9
&
]. Consistently, SSeCKS null
mice show hyperplasia of PECs in otherwise normal
glomeruli and develop significantly worse proteinu-
ric glomerular disease, marked by increased PEC pro-
liferation and expression of nuclear cyclin D1 [9
&
].
These observations suggest that PECs represent podo-
cyte progenitors that are maintaining a modulated
capacity to divide until they are in an undifferenti-
ated state [10]. Although PECs exhibit a simple cytos-
keleton and a high proliferative capacity, the highly
specialized podocyte phenotype requires the acqui-
sition of a complex cytoskeleton structure that would
be disrupted to assemble the mitotic spindle, making
it difficult to efficiently complete cytokinesis [10].
Consistently, in PECs, Notch activation triggers pro-
liferation by promoting entry into the S-phase of the
cell cycle and mitotic division (Fig. 1) [11]. However,
attenuation of Notch activity is required to allow
PECs todifferentiate into podocytes, asdemonstrated
by the observation that an impaired downregulation
of the Notch pathway induces generation of podo-
cytes with an abnormal DNA content and their
following death by mitotic catastrophe [11].
In summary, PECs represent progenitors for
podocytes during normal kidney development, dis-
playing the property to proliferate and amplify, a
capacity that no longer exists once PECs are com-
mitted to differentiate into podocytes [8,12]. Like
other progenitor cells [13], this process is regulated
through an interaction among the b-catenin/Wnt
signaling pathway and the Notch pathway [11,14],
which regulate PEC shift from entry within the cell
cycle and proliferation to exit from the cell cycle and
differentiation into podocytes (Fig. 1).Role of parietal epithelial cells as progenitor
cells to enhance podocyte number
The capacity of mature PECs to proliferate and
differentiate into podocytes beyond glomerular
development has been recently described in adult
human, mouse, and rat kidney [4,12,15,16]. In
humans, PECs represent a heterogeneous popu-
lation of progenitors, characterized by the coexpres-
sion of two surface markers, CD24 and CD133, used
to identify human stem or progenitor cells in several
adult human tissues [17,18]. PECs localized to the
urinary pole that express progenitor, but not podo-
cyte, markers can differentiate into tubular cells, as
well as podocytes [16]. By contrast, a subpopulation
of PECs localized along the Bowman’s capsule
expressing both progenitor and podocyte markersrized reproduction of this article is prohibited.
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localized to the vascular pole do not normally
express progenitor markers, but display phenotypic
features of fully differentiated podocytes [16]. In
contrast to other kidney cells, PECs expressing
CD24þCD133þ also express CD106. This expres-
sion profile distinguishes them from other
CD24þCD133þ cells scattered along the tubule,
displaying phenotypic and functional features of
tubular progenitors [19]. Although they only
partially share markers with human cells, PECs with
similar progenitor features and anatomical localiz-
ation were also identified in mouse and rat kidneys
[4,20
&
]. Indeed, cells with features of both PECs
and podocytes could be detected at the glomerular
vascular stalk in mouse [4].
The elegant genetic tagging of PECs in a triple-
transgenic doxycycline-inducible mouse line dem-
onstrated that podocytes are recruited from PECs,
which proliferate and differentiate from the urinary
to the vascular stalk, generating new podocytes [4].
In addition, in adult rat kidneys, three distinct cell
populations of PECs lining the rat Bowman’s capsule
have been identified, including the most abundant
one of immature progenitor cells, transitional cells
expressing markers for both progenitor cells and
podocytes, and a subset of differentiated cells, the
parietal podocytes [20
&
]. Recently, several studies
suggested the possibility that PECs also migrate from
Bowman’s capsule to the capillary tuft in regions
different from the vascular pole [21]. Interestingly,
the possibility of PECs differentiating into podo-
cytes in response to injury was recently hypo-
thesized also in adult zebrafish [22]. PECs begin to
express podocyte proteins in states of progressive
podocyte depletion, including experimental focal
segmental glomerulosclerosis (FSGS), membranous
nephropathy, and aging nephropathy [23,24].Role of parietal epithelial cells and filtered
albumin
Adjacent PECs adherent to the underlying
Bowman’s basement membrane exhibit tight
junctions, and express the tight junction proteins
claudin-1, occludin, and ZO-1 in normal rat, mouse,
and human glomeruli [25]. Tight junctions are
disrupted in experimental anti-glomerular base-
ment membrane (GBM) disease, accompanied by
reduced levels of these tight junction proteins
[25]. In an attempt to determine the biological con-
sequences of these changes, an in-vivo permeability
assay was performed using different-sized labeled
tracers. Following direct podocyte injury leading
to proteinuria, the permeability to tracers similar
in size to albumin was increased between adjacentCopyright © Lippincott Williams & Wilkins. Unau
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space into the periglomerular compartment [25].
The consequences of this remain unclear, although
one might speculate that the presence of glomerular
filtrate in the periglomerular space might be pro-
inflammatory.
Under normal conditions, PECs in culture and
PECs in vivo take up small amounts of albumin.
However, when cultured PECs are exposed to
increased albumin concentrations, albumin abun-
dance increases, in part due to endocytosis. Increased
intracellular albumin leads to apoptosis [26].
Similarly, PECs in vivo also show increased intracellu-
lar levels in experimental models of proteinuria,
accompanied by apoptosis. Taken together, through
tight junctions and endocytosis, PECs might nor-
mally play an important role in filtered albumin.PARIETAL EPITHELIAL CELLS AS THE BAD
GUYS IN DISEASE
Although the data discussed above is consistent
with PECs portrayed as vital cells for normal devel-
opment and glomerular repair, they paradoxically
also have a ‘bad side’ to them in certain disease
states, in which their responses directly contribute
to glomerular disease and, in certain circumstances,
deterioration in glomerular function.Parietal epithelial cell proliferation: role in
crescentic glomerulonephritis and collapsing
glomerulopathy
To date, there are no glomerular diseases considered
‘PEC-specific’. Crescentic glomerulonephritis is per-
haps the best-known disease in which PECs contrib-
ute significantly to the kidney disease, although the
initial injury likely arises in the glomerular endo-
thelial cells, podocytes, and/or GBM. The cellular
crescent is a unique glomerular lesion that implies
glomerular epithelial cell overgrowth to fill-up
Bowman’s space that compromises glomerular
function. There has been a debate about the type
of epithelial cells inside crescents, because crescentic
lesions often stain positive for both PEC and podo-
cyte markers [27,28]. However, elegant lineage
tracing studies in mice have finally demonstrated
clearly that PEC proliferation leads to marked
increase in cell number within crescents of murine
nephrotoxic serum nephritis and collapsing glomer-
ulopathy [29]. The concept that the low mitotic
activity of terminally differentiated podocytes could
increase via ‘dedifferentiation’ to podocyte hyper-
plasia-related crescents, which was before solely
based on immunostaining, was finally disproved
by these lineage-tracing studies [29]. In hindsight,thorized reproduction of this article is prohibited.
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staining positive for podocyte markers is rather
due to the expression of such proteins by activated
PECs [23]. In addition, podocytes sometimes
stain positive for proliferation markers like Ki67
or BrdU, but this indicates cell-cycle entry and
not necessarily podocyte mitosis. During glomeru-
lar injury, podocytes certainly enter the S-phase of
the cell cycle to undergo hypertrophy, whereas
when being forced to override the G2/M check
point of the cell cycle, they usually undergo an
aberrant mitosis leading to podocyte detachment
and death, that is, mitotic catastrophe [10,11].
Finally, studies on human renal biopsy material
are consistent with the concept that it is the PEC
overgrowth that accounts for epithelial hyperplasia
in crescentic and collapsing glomerulopathies
[30].
What factors/pathways drive the mitotic activity
of PECs in these disorders? Crescent formation most
frequently occurs in necrotizing and highly inflam-
matory forms of glomerulonephritis, which has
raised the concept that it is the inflammatory
component that accounts for crescent formation.
However, crescents develop in multiple other
glomerulopathies including late-stage glomerulo-
sclerosis and non-inflammatory glomerulopathies.
The group led by Moeller showed that in a transgenic
mouse model of selective PEC depletion with
diphtheria toxin, PEC necrosis leading to loss is
sufficient to drive crescent formation. This is most
likely due to an ‘overcompensatory’ epithelial repair
response, driven by surviving PECs [31]. Even though
this study proves the PEC’s capacity to create hyper-
plastic lesions and crescents upon injury, selective
PEC necrosis is not a typical feature of common
crescentic glomerulopathies, which, rather, display
necrotic lesions of the glomerular tuft. Tuft necrosis
involves glomerular vascular injury, and accumulat-
ing evidence suggests that plasma leakage provides
mitogenic stimuli that drive PEC hyperplasia and
crescent formation. PECs (like other epithelial cells)
usually live in an environment devoid of plasma
exposure. The rupture of glomerular capillaries in
crescentic disease increases the plasma concentration
inside Bowman‘s space by 20–40%. Experimentally,
this milieu dramatically increases the proliferation of
murine and human PECs in culture [32
&
]. Several
plasma components could account for this PEC
hyperplasia but, currently, there are consistent data
only for fibrinogen activation, an element of the
activated coagulation cascade during vascular inju-
ries. A lack of fibrinogen or fibrinolysis prevents PEC
hyperplasia formation in several rodent models of
glomerular crescent formation [32
&
,33]. PDGF-D,
CXCR4,andepidermalgrowth factor receptor (EGFR)opyright © Lippincott Williams & Wilkins. Unautho
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[34,35], but the related evidence originates from
experimental overexpression, which does not mirror
physiological conditions. In addition, in these
studies, the transgene was overexpressed in podo-
cytes, so PECs were only indirectly affected. Angio-
tensin-converting enzyme (ACE) inhibition helps to





remains unclear whether this relates to the hemody-
namic or the paracrine effects of angiotensin II.
Cellular crescents can progress to fibrocellular
crescents, due to the accumulation of extracellular,
and potentially irreversible, matrix deposits that
predict a poor renal outcome. This process might
be the result of PEC epithelial-to-mesenchymal tran-
sition, characterized by a loss of epithelial polarity
and increased secretion of extracellular matrix com-
ponents. The loss of polarity becomes obvious by
the fact that PECs that undergo this process secrete
extracellular matrix to not only their basal aspect
but also all around like mesenchymal cells, which




Another glomerulopathy that was recently
related to an abnormal PEC proliferation hyper-
plasia is collapsing glomerulopathy. Collapsing
glomerulopathy is characterized histologically by
segmental to global collapse of the capillary tuft
and pronounced epithelial cell hyperplasia, often
referred as pseudo-crescents. Lineage tracing studies
demonstrated that these monolayer lesions located
directly on top of the glomerular convolute con-
sisted of genetically tagged PECs that proliferate in a
dysregulated manner in response to massive podo-
cyte injury, further suggesting that the type of PEC
response to podocyte injury is an important driver of
progression toward glomerulosclerosis.Parietal epithelial cells and glomerular
scarring
FSGS, characterized by scarring in a segment of
glomeruli, has traditionally been considered prim-
arily a disease of podocytes. One of the earliest
hallmarks of classic FSGS is the formation of a
synechial attachment, in which the glomerular tuft
and Bowman’s capsule become adherent. The
traditional view has been that the segmental
scarring was a consequence of injured or damaged
podocytes, as these cells have the ability to produce
a variety of extracellular matrix proteins. However, a
role for PECs in this sclerotic process has emerged
over recent years as follows. In the era predating
currently used cell fate mapping techniques, several
well performed studies using immunostaining for
cell ‘specific’ markers showed the presence of PECsrized reproduction of this article is prohibited.
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disease [36,37]. These studies suggested that PECs
might participate in the focal sclerotic glomerular
process.
Subsequently, utilizing PEC-reporter mice,
Smeets et al. [38
&&
] have provided convincing data
for the role of PECs producing matrix proteins, and
thereby significantly contributing to the segmental
scarring process. They showed that following a
primary injury to podocytes in these mice, PECs
become ‘activated’ as denoted by the de-novo
expression of CD44. In this activated state, PECs
begin to produce extracellular matrix proteins,
which initially accumulate along Bowman’s base-
ment membrane, leading to thickening of this
structure. They also showed that activated PECs
can later be detected on the glomerular tuft, where
they continue to produce Bowman’s capsule type
matrix [38
&&
]. Similar observations were reported
also in human biopsies [39
&&
]. The continuum of
newly made Bowman’s capsule-type matrix by PECs
at these two adjacent sites ultimately leads to a
‘bridge’ of matrix that extends from Bowman’s
basement membrane to the glomerular tuft, com-
prising the characteristic fibrous attachment/
adhesion of these two structures in FSGS. As more
PECs invade the glomerular tuft, extracellular
matrix proteins continually and progressively
accumulate beyond this original site, ultimately
leading to an advanced sclerotic lesion of FSGS.
More recently, transcriptomic studies add further
evidence for a role of PECs in matrix accumulation,
wherein an abundance of genes considered
‘PEC-specific’ were detected in areas of sclerosis in
human glomeruli [40]. Thus, one current view
underlying the mechanism of segmental scarring
in FSGS is that the extracellular matrix accumu-
lation likely arises from two sources: injured
podocytes and activated PECs. Definitive cause-
and-effect studies are still needed.
A recent study in human glomerular diseases
showed that similar to experimental conditions of
FSGS, PECs begin to express de novo CD44, a glyco-
protein involved in cell adhesion, cell matrix inter-
action, and cell migration [29,31,38
&&
]. Noteworthy
was that in human biopsies from patients with
minimal change disease (also a podocyte disease),
CD44 was barely expressed [39
&&
]. Although the
precise biological consequence of increased CD44
expression in PECs is unclear, CD44 staining might
serve as a useful ‘marker’ to distinguish between
FSGS and minimal change disease in kidney biop-
sies. Finally, PECs (in addition to podocytes) have
also been detected in the urine of patients with
active FSGS [41], although the consequences of this
too remain unclear.Copyright © Lippincott Williams & Wilkins. Unau
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therapeutic target in disease
Like most kidney cells, there are no reports on cell-
specific drug targets in PECs. However, the discovery
that adult PECs can differentiate into podocytes
provides hope that this pathway might be pharma-
cologically modulated in order to enhance new
podocyte formation. Several reports show that PECs
are responsive to certain therapeutics. ACE inhi-
bition reduces PEC proliferation in experimental
human immune deficiency associated nephropathy
(HIVAN) [42], and ACE inhibition has also been
demonstrated to enhance the capacity of PECs to
become progenitor cells [20
&
]. Zhang et al. [43
&
]
showed that administering retinoids to animals
with experimental FSGS or membranous nephrop-
athy augmented the number of PECs that express
podocyte proteins, suggesting that under these
circumstances, retinoids might enhance the progen-
itor capacity of PECs. The precise role for vitamin D
in PEC biology is unknown, but might be of import-
ance, as the vitamin D receptor is expressed on PECs
[44], and vitamin D is required for the differen-
tiation of PECs toward podocytes in culture [45].
In addition, it was recently demonstrated that glo-
merular regeneration could be modulated using
Notch inhibitors in mouse models of FSGS, thus
directly influencing the amount of proteinuria
and the occurrence of glomerulosclerosis [11].
Recent studies suggest that blockade of the chemo-
kine stromal derived factor-1 (SDF-1/CXCL12) also
increases podocyte number, reduces proteinuria,
and ameliorates renal dysfunction in nephropathy
of type 2 diabetic mice by enhancing PEC differen-
tiation toward the podocyte phenotype [46,47].
Indeed, CXCL12 blockade increased renal mRNA
expression levels of nephrin and podocin, two podo-
cyte-slit membrane-related proteins that serve as
markers of podocyte differentiation [47], further
suggesting that pharmacological treatments can
be used to modulate PEC growth and/or differen-
tiation into podocytes. Other potential therapeutic
targets for PECs in disease might include epidermal
growth factor [48] and its receptor [49], as well as the
amino acid transporter LAT2 [50]. More recently,
Ueno et al. [51] showed that inhibiting Notch in vivo
in experimental collapsing FSGS reduced the expres-
sion of mesenchymal-like markers including alpha
smooth muscle actin, vimentin, and snail.CONCLUSION
Our understanding of the biology and pathophysi-
ology of PECs is increasing substantially, as it relates
to how these glomerular epithelial cells might be
reparative on the one hand, yet injurious on thethorized reproduction of this article is prohibited.
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get us to the next level of understanding on what
triggers and regulates these processes, and which
molecular targets we might want to alter to hasten
repair and reduce progression of glomerular disease.
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